Clinical efficacy and safety of apatinib as maintenance treatment in patients with advanced esophageal squamous cell carcinoma

References

• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132.
   PubMed Web of Science ®Google Scholar
• Vaghjiani RG, Molena D. Surgical management of esophageal cancer. Chin Clin Oncol. 2017;6:47.
   PubMed Web of Science ®Google Scholar
• Yoshimoto Y, Kono K, Suzuki Y. Anti-tumor immune responses induced by radiotherapy: A review. Fukushima J Med Sci. 2015;61:13–22.
   PubMedGoogle Scholar
• Huang FL, Yu SJ. Esophageal cancer: risk factors, genetic association, and treatment. Asian J Surg. 2018;41:210–215.
   PubMed Web of Science ®Google Scholar
• Aoyama T, Yoshikawa T. Targeted therapy: apatinib - new third-line option for refractory gastric or GEJ cancer. Nat Rev Clin Oncol. 2016;13:268–270.
   PubMedGoogle Scholar
• Guo Y, Tang J, Huang XE, et al. Efficacy and toxicity of apatinib combined with or without chemotherapy for patients with advanced or metastatic chemotherapy-refractory gastric adenocarcinoma: a prospective clinical study. Medicine (Baltimore). 2019;98:e13908.
   PubMed Web of Science ®Google Scholar
• Eswarappa SM, Fox PL. Antiangiogenic VEGF‐Ax: A new participant in tumor angiogenesis. Cancer Res. 2015;75:2765‐2769.
   PubMed Web of Science ®Google Scholar
• Liu Y, Litiere S, de Vries EG, et al. The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: results of a survey in the oncology community. Eur J Cancer. 2014;50:260–266.
   PubMed Web of Science ®Google Scholar
• Zhang YQ, Zhang JJ, Song HJ, et al. Expression and prognostic influence of NF—KB and EGFR in esophageal cancer. Genet Mol Res. 2015;14(4):16819–16826.
   PubMed Web of Science ®Google Scholar
• Hiroyuki D, Ken K. Updates in the 8th edition of the TNM staging system for esophagus and esophagogastric junction cancer. Jpn J Clin Oncol. 2020;50(8):847–851.
   PubMed Web of Science ®Google Scholar
• Ter Veer E, Haj Mohammad N, van Valkenhoef G, et al. Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature. Cancer Metastasis Rev. 2016;35:439–456.
   PubMed Web of Science ®Google Scholar
• Chen LT, Oh DY, Ryu MH, et al. Anti-angiogenic therapy in patients with advanced gastric and gastroesophageal junction cancer: a systematic review. Cancer Res Treat. 2017;49:851–868.
   PubMed Web of Science ®Google Scholar
• Xu WW, Li B, Cheung AL. The potential of targeted antiangiogenesis therapies in the treatment of esophageal cancer. Gastrointest Cancer. 2015;5:79–88.
   Google Scholar
• Xu WW, Li B, Lam AK, et al. Targeting VEGFR1- and VEGFR2-expressing non-tumor cells is essential for esophageal cancer therapy. Oncotarget. 2015;6:1790–1805.
   PubMed Web of Science ®Google Scholar
• Lin YC, Liu CY, Kannagi R, et al. Inhibition of endothelial SCUBE2 (signal peptide-CUB-EGF domain-containing protein 2), a novel VEGFR2 (vascular endothelial growth factor receptor 2) coreceptor, suppresses tumor angiogenesis. Arterioscler Thromb Vasc Biol. 2018;38:1202–1215.
   PubMed Web of Science ®Google Scholar
• Scott AJ, Messersmith WA, Jimeno A. Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors. Drugs Today (Barc). 2015;51(4):223–229.
   PubMed Web of Science ®Google Scholar
• Zhang H. Apatinib for molecular targeted therapy in tumor. Drug Des Devel Ther. 2015;9(11):6075–6081.
   PubMed Web of Science ®Google Scholar
• Lin Y, Zhai E, Liao B, et al. Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates apatinib treatment efficacy in gastric cancer. Oncotarget. 2017;8:11990–12002.
   PubMedGoogle Scholar
• Paccez JD, Duncan K, Vava A, et al. Inactivation of GSK3β and activation of NF-κB pathway via Axl represents an important mediator of tumorigenesis in esophageal squamous cell carcinoma. Mol Biol Cell. 2015;26(5):821–831.
   PubMed Web of Science ®Google Scholar
• Lin C, Song L, Gong H, et al. Nkx2-8 downregulation promotes angiogenesis and activates NF-κB in esophageal cancer. Cancer Res. 2013;73:3638–3648.
   PubMed Web of Science ®Google Scholar
• Weiyun Z, Yingying L, Daxiong Z. Secondary cavitary pulmonary tuberculosis after apatinib treatment in lung squamous cell cancer. Am J Ther. 2020;27(3):e310–e312.
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34:1448–1454.
   PubMed Web of Science ®Google Scholar
• Scott LJ. Apatinib: A review in advanced gastric cancer and other advanced cancers. Drugs. 2018;78(7):759–775.
   PubMed Web of Science ®Google Scholar
• Song Z, Yu X, Lou G, et al. Salvage treatment with apatinib for advanced non-small-cell lung cancer. Onco Targets Ther. 2017;10:1821–1825.
   PubMed Web of Science ®Google Scholar
• Roviello G, Ravelli A, Polom K, et al. Apatinib: a novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. Cancer Lett. 2016;372:187–191.
   PubMed Web of Science ®Google Scholar
• Zhao S, Ren S, Jiang T, et al. Low-Dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-l1 blockade in lung cancer. Cancer Immunol Res. 2019;7:630–643.
   PubMed Web of Science ®Google Scholar
• Li J, Wang L. Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma. Onco Targets Ther. 2017;7(10):3965–3969.
   Google Scholar
• Procaccio L, Damuzzo V, Di Sarra F, et al. Safety and tolerability of anti-angiogenic protein kinase inhibitors and vascular-disrupting agents in cancer: focus on gastrointestinal malignancies. Drug Saf. 2019;42:159–179.
   PubMed Web of Science ®Google Scholar